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Abstract
To date, there are no effective pharmacotherapies for treating psychostimulant abuse. Previous
preclinical and clinical studies have shown that continuous treatment with the monoamine releaser
amphetamine reduces cocaine self-administration, but amphetamine selectively targets the dopamine
system and is reinforcing. In the present study, we examined the consequences of administration of
amphetamine and three structurally-related analogs that vary in their potencies for releasing
dopamine and serotonin on behavioral-stimulant effects and nucleus accumbens dopamine levels in
squirrel monkeys. Amphetamine and PAL-353, which have relatively high selectivity for releasing
dopamine vs. serotonin, increased accumbens dopamine levels and induced stimulant effects on
behavior maintained by a fixed-interval schedule of reinforcement. PAL-313, which has relatively
low selectivity for releasing dopamine vs. serotonin, increased dopamine levels, but did not induce
behavioral-stimulant effects. PAL-287, which is relatively nonselective in releasing dopamine and
serotonin, did not increase dopamine levels or induce behavioral-stimulant effects. These results
demonstrate that increasing serotonergic activity attenuates dopamine release and dopamine-
mediated behavioral effects of monoamine releasers. In addition, these results support further
investigation of PAL-313 and similar compounds as a potential medication for treating
psychostimulant abuse.
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Psychostimulant abuse is a significant public health problem, with 2.1 million Americans
reporting cocaine use and 1.9 million reporting methamphetamine use in 2006 (Substance
Abuse and Mental Health Services Administration (SAMHSA), 2007). Unfortunately, there
are no currently FDA-approved pharmacotherapies to treat stimulant dependence (Volkow and
Li, 2004). Agonist substitution therapies have been successful in treating patients dependent
on opioids (Kreek, 2000) or nicotine (Henningfield, 1995). Thus, drugs that have
pharmacological and behavioral effects similar to those of psychostimulants have the potential
to be effective medications for psychostimulant abuse. In order to identify these potential
medications, there needs to be a better understanding of how psychostimulants produce their
behavioral and neurochemical effects.
Psychostimulants interact with monoamine (dopamine, norepinephrine, and serotonin) neurons
in the central nervous system. These neurons express specialized plasma membrane proteins
that transport monoamines from the extracellular space back into the cytoplasm. Binding to
these transporter proteins [dopamine transporter (DAT), norepinephrine transporter (NET),
and serotonin transporter (SERT)] is the principal mechanism for inactivation of monoamine
signaling (Howell and Kimmel, 2008). Drugs that interact with these transporters can be
categorized as either reuptake inhibitors or substrate-type releasers, based on their mechanism
of action. Reuptake inhibitors bind to transporters without being taken up into the cell. This
binding blocks the reuptake of released neurotransmitter molecules, thereby elevating
extracellular neurotransmitter levels in an impulse-dependent fashion. In contrast, substrate-
type releasers bind to the transporter proteins and are then transported into the cytoplasm of
nerve terminals. These releasers elevate extracellular neurotransmitter levels in two ways: by
promoting efflux of the transmitter through the transporter protein and by increasing
cytoplasmic transmitter levels by disrupting transmitter storage in vesicles (Rudnick, 1997;
Rudnick and Clark, 1993; Sulzer et al., 2005).
Although cocaine is a nonselective inhibitor of all three monoamine transporters (Madras et
al., 1989; Reith et al., 1986), the behavioral effects of cocaine associated with its abuse liability
have been attributed primarily to its actions at DAT (Ritz et al., 1987). This has been
substantiated in rodent, nonhuman primate, and clinical studies. A relationship between the
potency of cocaine analogs at binding to the DAT in vitro and the potency of these analogs in
vivo has been demonstrated by their locomotor-stimulant effects in rodents (Cline et al.,
1992; Kuhar, 1993) and their cocaine-like behavioral effects in squirrel monkeys (Bergman et
al., 1989; Madras et al., 1989; Spealman et al., 1989). The relevance of the DAT in the abuse
liability of cocaine has been supported further by neuroimaging studies. In human cocaine
users, a significant correlation was observed between the level of DAT occupancy and the
magnitude of the subjective high following administration of cocaine (Volkow et al., 1997) or
the behavioral stimulant methylphenidate (Volkow et al., 1999). Similarly, the abuse-related
behavioral effects of monoamine releasers, such as amphetamine and methamphetamine, have
been attributed to their effects on dopamine (Hanson et al., 2004; Koob and Bloom, 1988;
Wise, 1996; Wise and Bozarth, 1987).
The purpose of the present study was to investigate the neurochemical and behavioral effects
of mixed-action monoamine releasers in squirrel monkeys. Amphetamine and three structurally
related analogs (Figure 1) were selected for comparison in these studies. While these drugs are
equipotent in releasing dopamine in in vitro studies conducted in rodent tissue (Table 1), they
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vary in their potency for releasing serotonin. Within the group of selected compounds,
amphetamine and PAL-353 are similar in their DA/5-HT releasing potency ratio, in that both
are very selective for releasing dopamine. PAL-313 is less selective for dopamine, and
PAL-287 even less so. The serotonin selective releaser fenfluramine was added to the
behavioral studies for comparison. Our hypothesis was that, as the selectivity for serotonin
release increased, drug-induced increases in extracelluar dopamine would decrease and drug-
induced increases in locomotor activity would decrease accordingly.
METHODS
Subjects
Ten adult male squirrel monkeys (Samiri sciureus) weighing 700–1200 g served as subjects.
Animals lived in individual home cages and had daily access to food (Harlan Teklad monkey
chow; Harlan Teklad, Madison, WI; fresh fruit and vegetables) and unlimited access to water.
All monkeys had prior exposure to cocaine and other drugs with selective dopaminergic or
glutamatergic activity in various behavioral studies. Animal use procedures were in strict
accordance with the National Institutes of Health “Guide for Care and Use of Laboratory
Animals” (Publication No. 85-23, revised 1985) and were approved by the Institutional Animal
Care and Use Committee of Emory University.
Apparatus
During daily behavioral test sessions, each of six animals was seated in a Plexiglas chair within
a ventilated, sound-attenuating chamber (MED Associates, Georgia, VT). The chair was
equipped with stimulus lights, a response lever, and a tail stock for delivering a mild electrical
stimulus. Behavioral test sessions lasted approximately 90 min each day, five days per week.
During microdialysis experiments in a separate group of four animals, subjects were seated in
a chair and fitted with an adjustable Lexan neckplate that was positioned perpendicular to the
medial plane of the body just above the shoulder. These subjects had been acclimated to the
chair and neckplate over several months prior to the start of these experiments. At least two
weeks elapsed between microdialysis experiments.
Guide Cannulae Implantation
A stereotaxic apparatus was used to implant CMA/11 guide cannulae (CMA/Microdialysis,
Acton, MA) bilaterally to target the nucleus accumbens of four monkeys in a procedure
described previously (Czoty et al., 2000). Anesthesia was initiated with Telazol (tiletamine
hydrochloride and zolazepam hydrochloride, 3.0 mg) and atropine. Inhaled isoflurane (1.0–
2.0%) was administered to maintain depth of anesthesia during the procedure. A stainless steel
stylet was placed in each guide cannulae when not in use. Analgesics [Banamine (flunixin
meglumine)] and antibiotics [Rocephin (ceftriaxone)] were prescribed as necessary by
veterinary staff. Animals were closely monitored during recovery from anesthesia, and a
minimum of two weeks elapsed before microdialysis experiments were performed.
Stimulus Termination Procedures
Six animals were trained under a fixed-interval (FI) 300-s schedule of stimulus termination.
At the beginning of the testing session, the behavioral chamber was illuminated with a red light
for 300 s. When this interval had elapsed, the monkey had 3 s to press the lever one time to
terminate the red light, which was associated with an impending electrical stimulus. Upon
termination of the red light, a white light was illuminated for 15 s, followed by a 60-s timeout.
If the lever was not pressed during the 3-s period, the animal received a 3-mA stimulus for
approximately 200 ms to the tail, followed by a 60-s timeout. Responding during timeout
periods had no scheduled consequences. Animals were tested each day, five days per week,
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and each daily session consisted of fifteen FI components. When rates and patterns of
responding had stabilized such that there was less than 10% variability in response rate for five
consecutive test days, drug experiments were initiated.
A single dose of drug or saline was administered i.m. in the thigh 5 min before the beginning
of the experimental session. Animals were tested, but did not receive drug on Mondays and
Wednesdays. They received a single dose of test drug on Tuesdays and Fridays, and saline was
administered prior to the session on Thursdays, as a control for the injection procedure. Animals
received each dose of each drug in ascending order. The animals used in this study had a
response rate of 0.36 ± 0.03 (group mean ± SEM) presses per second when given saline.
Microdialysis procedures
CMA/11 dialysis probes with a shaft length of 20 mm and active dialysis membrane measuring
2 mm long and 0.24 mm diameter were flushed with artificial cerebrospinal fluid (1.0 mM
Na2HPO4, 150 mM NaCl, 3 mM KCl, 1.3 mM CaCl2, 1.0 mM MgS04 and 0.15 mM ascorbic
acid, final pH=7.4–7.56) for at least 20 min. Probes were inserted into the guide cannulae and
connected to a Harvard PicoPlus microinfusion pump via FEP Teflon tubing. Probes were
perfused with artificial cerebrospinal fluid at 2.0 μl/min for the duration of the experiment.
Samples were collected every 6 min in microcentrifuge tubes and immediately refrigerated.
Following a 60-min equilibration, four consecutive 6-min samples were collected for
determination of baseline dopamine concentration. Following collection of baseline samples,
saline or a dose of a test drug was administered i.m. and 6-min samples were collected for an
additional 90 min. Animals were tested a maximum of one time every other week, and both
sites were accessed in each study. This regimen of repeated access has produced consistent
responses to drug treatment without significant gliosis (Czoty et al., 2000).
High-performance liquid chromatography (HPLC) and electrochemical detection were used
to quantify levels of dopamine. The HPLC system consisted of a small bore (3.2 mm × 150
mm, 3 micron) column (ESA, Inc., Chelmsford, MA) with a commercially available mobile
phase (MD-TM, ESA, Inc.) delivered by an ESA 582 solvent delivery pump at a flow rate of
0.6 ml/min. After loading onto the refrigerated sample tray, samples (12 μl) were automatically
mixed with 3 μl of ascorbate oxidase, and 5 μl of this mixture was injected into the HPLC
system by an ESA Model 542 autosampler. Samples were analyzed within 12 hours of
collection, remaining either in a refrigerator or in the refrigerated autosampler tray during this
time. Electrochemical analyses were performed using an ESA dual-channel analytical cell
(model 5040) and guard cell (model 5020, potential = 350 mV) and an ESA Coulochem II
detector. The potential of channel 1 was set to −150 mV for oxidation, while the potential of
channel 2 was set to 275 mV for reduction. A full range of dopamine standards (0.5–25 nM)
was analyzed both before and after each set of samples to evaluate possible degradation of
dopamine. Levels of dopamine below 0.1 nM were considered below the limit of detection. A
desktop computer collected data and chromatograms were generated by EZChrom Elite
software (version 3.1, Scientific Software, Pleasanton, CA). The chromatograms were
analyzed using the EZChrom software, comparing the area under the curve of the experimental
samples with that of the standards. The neurochemical effects of the drugs were compared with
the neurochemical effects of saline and cocaine. Basal levels of dopamine were between 3–5
nM, unadjusted for probe recovery, as reported in earlier studies (Czoty et al., 2000). Before
and after each in vivo experiment, probes were tested in vitro to determine suitability of the
probes. Percent recovery was similar for all probes (10–20%).
Drugs
Amphetamine (Sigma Aldrich, St. Louis, MO) was dissolved in 0.9% saline, while PAL-287,
PAL-313, and PAL-353 (Research Triangle Institute, Research Triangle, NC), and
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fenfluramine (Sigma Aldrich, St. Louis, MO) were dissolved in sterile water. Drug doses were
determined as salts. Drug injections were administered into the thigh muscle in a volume of
0.4 to 0.8 ml in both the behavioral and microdialysis studies.
Data analysis and statistics
Each microdialysis time course curve was analyzed using a one-way ANOVA. When a
significant main effect was detected, the time points following drug administration were
compared to the zero time point using Dunnett’s post hoc test. The overall rate data for each
drug in the behavioral-stimulant dose-effect curves (Figure 3) was analyzed using a repeated-
measures one-way ANOVA. When a significant main effect was detected, each dose was
compared to vehicle using Dunnett’s post hoc test. The time-course behavioral-stimulant data
(Figure 4) were analyzed such that each dose of each drug was compared to vehicle using a
repeated-measures two-way ANOVA. When a significant main effect was detected, each time
point following drug administration was compared to the corresponding time point following
vehicle administration using Bonferroni post-hoc tests.
RESULTS
For the in vivo microdialysis studies, the same dose for each drug was selected (1.0 mg/kg,
i.m.), as they are approximately equipotent in releasing dopamine as measured by in vitro
assays using rodent tissue (Table 1). Administration of PAL-353 had a significant effect (F
(18,54) = 5.343, p < 0.001) and produced the greatest increase in extracellular dopamine in the
nucleus accumbens (Figure 2), with a peak of 1612% of basal dopamine levels 36 min after
drug injection. There was a significant main effect of amphetamine administration (F(18,54)
= 7.017, p < 0.001), which produced a peak increase of 579% of basal dopamine levels at 18
min after drug injection. Administration of PAL-313 produced a peak increase of 442% of
basal dopamine levels at 42 min after drug injection, and there was a significant main effect
of this drug (F(18,54) = 3.217, p < 0.001). Administration of PAL-287 produced a peak increase
of 106% of basal dopamine levels at 30 min after drug injection. In contrast to the other three
drugs, there was not a significant main effect of PAL-287 (F(18,54) = 1.230, NS).
The effects of a single i.m. administration of each of a range of doses of each drug on the rate
of lever-pressing behavior was examined in a group of six squirrel monkeys that was trained
on a fixed-interval schedule (Figure 3). The data are expressed as an average of the response
rate as a percent of baseline responding following saline administration over the entire 90-min
session. This baseline response following saline administration was reassessed between each
set of dose-response determinations. Administration of amphetamine (0.03–1.0 mg/kg)
significantly increased response rates above baseline levels (F(4,20) = 23.265, p < 0.0001) in
an inverted U-shaped manner, with a peak at 0.3 mg/kg. Administration of PAL-353 (0.03–
1.7 mg/kg) also significantly increased response rates above baseline levels (F(5,25) = 9.806,
p < 0.001) in an inverted U-shaped manner, with a peak at 0.3 mg/kg. Administration of
PAL-313 (0.03–1.7 mg/kg) significantly altered response rates, as compared to baseline levels
(F(5,25) = 15.427, p < 0.001), such that 1.7 mg/kg significantly decreased responding to below
baseline levels. Administration of PAL-287 (0.03–3.0 mg/kg) also significantly altered
response rates (F(5,25) = 8.408, p < 0.001), such that 1.0 mg/kg significantly increased
responding above baseline levels, but 3.0 mg/kg significantly decreased responding to below
baseline levels. Lastly, administration of fenfluramine (0.3–3.0 mg/kg) significantly altered
response rates (F(3,15) = 4.474, p = 0.020), such that 3.0 mg/kg significantly decreased
responding below baseline levels.
The full time course of behavioral-stimulant effects of 0.3 and 1.0 mg/kg amphetamine and
PAL-353 are presented in Figure 4, along with the effects of vehicle administration. In general,
0.3 mg/kg amphetamine increased response rates, while 1.0 mg/kg suppressed response rates
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(Figure 4A). Administration of 0.3 mg/kg amphetamine resulted in a peak increase of 358%
basal activity 48 min after administration. There was a significant main effect of drug (F(1,5)
= 32.227, p = 0.002) and of time (F(14,70) = 2.584, p = 0.005), but not of the interaction (F
(14,70) = 1.466, NS). Administration of 1.0 mg/kg amphetamine resulted in a peak increase
of 136% basal activity 12 min after administration, as well as a peak decrease of 39% basal
activity 24 min. The main effects of both drug and time for this dose of amphetamine just
missed statistical significance (F(1,5) = 5.269, p = 0.07; F(14,70) = 1.783, p = 0.059).
In general, both doses of PAL-353 increased response rates, although this effect was not dose-
related (Figure 4B). Administration of 0.3 mg/kg PAL-353 resulted in a peak increase of 377%
basal activity 18 min after administration. There was a significant main effect of drug (F(1,5)
= 53.380, p < 0.0001) and of time (F(14,70) = 14.0875, p < 0.0001), as well as a significant
interaction (F(14,70) = 7.04, p < 0.001). Administration of 1.0 mg/kg PAL-353 resulted in a
peak increase of 306% basal activity 18 min after administration. There was a main effect of
drug (F(1,5) = 7.687, p = 0.039 and of time (F(14,70) = 2.895, p = 0.002), but not of the
interaction (F(14,70) = 0.843, NS).
DISCUSSION
The in vivo microdialysis studies described here show that acute systemic administration of
amphetamine, PAL-353, and PAL-313 significantly increased dopamine levels in the nucleus
accumbens in squirrel monkeys. The magnitude of this effect varied, such that the largest
increase was observed following administration of PAL-353, followed by amphetamine and
PAL-313. In contrast, administration of PAL-287 did not increase dopamine levels above
baseline. In a separate group of squirrel monkeys, administration of amphetamine and PAL-353
induced behavioral-stimulant effects, while administration of PAL-313, PAL-287, and
fenfluramine decreased response rates. In vitro assays using rodent tissue indicate that the four
PAL drugs are nearly equipotent in releasing dopamine and norepinephrine, but their potencies
in releasing serotonin vary (Negus et al., 2007; Rothman et al., 2001; Wee et al., 2005). Based
on the literature, the rank order for releasing dopamine vs. serotonin of these drugs is
amphetamine = PAL-353 > PAL-313 > PAL-287, and the current microdialysis and behavioral
data reflect this order.
Earlier studies in rodents indicated that administration of amphetamine and PAL-353 increased
locomotor activity, but PAL-313 and PAL-287 did not (Rothman et al., 2005; Wellman et al.,
2009). The behavioral-stimulant effect of drugs in rodents is often associated with abuse
liability in humans (Wise and Bozarth, 1987), although a dissociation between these two
characteristics has been noted (Donovan et al., 1999; Rocha et al., 1998). Rhesus monkeys
trained on a fixed-ratio schedule self-administered PAL-353, as did those trained on a
progressive-ratio schedule (Wee et al., 2005). While PAL-313 maintained self-administration
behavior in these same animals, the animals did not take as many infusions of PAL-313 as they
did of PAL-353. In a separate study, rhesus monkeys trained on a fixed-ratio schedule did not
self-administer PAL-287 across a range of doses (0.01–0.3 mg/kg/inf), although they readily
self-administered cocaine (Rothman et al., 2005). These results suggested that the increased
potency for releasing serotonin of PAL-313 and PAL-287 decreased the reinforcing
effectiveness of these drugs, and the current results suggest that this mechanism is also involved
in the blunted effect on extracellular dopamine release and operant behavior observed after
drug administration. The current data also support earlier evidence that increasing serotonin
release can attenuate drug-induced increases in dopamine levels in rodents and nonhuman
primates (Czoty et al., 2002; Di Matteo et al., 2008). However, PAL-287 is also a partial agonist
at the 5HT2C receptor (Rothman et al., 2005), which may also contribute to the decreased
behavioral stimulant and rewarding effects of this drug (Bubar and Cunningham, 2008,
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2006). In contrast, PAL-313 and PAL-353 are not active at this receptor (unreported
observations, Blough).
One surprising result of these studies was that the magnitude of drug-induced dopamine
increase in the microdialysis study was much larger for PAL-353 than for amphetamine,
although these two drugs are chemically very similar and have very similar ratios of dopamine
to serotonin release. In contrast to the large difference in neurochemical effects, the maximal
increase in locomotor activity was similar for PAL-353 and amphetamine. The similarity in
the magnitude of the behavioral-stimulant effect of these two drugs has also been observed in
rats following i.p. administration (Wellman et al., 2009). In the present study, the 1.0 mg/kg
dose of each of these drugs was on the descending limb of the dose-effect curve for behavioral
effects, but 1.0 mg/kg PAL-353 still had a significant behavioral-stimulant effect, while 1.0
mg/kg amphetamine did not. Initially, this difference appears to be explained by the
microdialysis data, as administration of 1.0 mg/kg PAL-353 produced a larger increase in
dopamine than did the administration of 1.0 mg/kg amphetamine. However, the descending
limb of behavioral effects of psychostimulants is generally attributed to stereotypy or
unconditioned behavior (Katz, 1989; Skjoldager et al., 1991), not to decreases in dopamine
release. Previous studies have shown that psychostimulants increase extracellular dopamine
levels in a dose-dependent manner and do not result in an inverted U-shaped curve (Chen and
Reith, 1994; Church et al., 1987; Hemby et al., 1995). Therefore, the decrease in behavioral
output following 1.0 mg/kg amphetamine may not be due to a decrease in extracellular
dopamine levels but could be a result of unconditioned behaviors resulting from increased
dopamine levels. Alternatively, this relatively high dose of amphetamine may have increased
extracellular serotonin to a level that augmented serotonin receptor activation, thus suppressing
the observed behavioral output. In support of this hypothesis, PAL-313 did not alter response
rates in the current study, although this drug increased dopamine levels to a maximum of 340%
baseline at a dose of 1.0 mg/kg. Previous studies have shown that drugs that increase dopamine
levels to 150–300% above baseline in the striatum, such as cocaine and tropane analogs of
cocaine, also produce significant increases in operant behavior (Ginsburg et al., 2005; Kimmel
et al., 2007). That neither 1.0 mg/kg amphetamine nor PAL-313 increased response rates
despite increasing dopamine levels suggests that increased serotonin release also alters post-
synaptic events, resulting in behavioral-stimulant effects that are lower than what one would
predict based on the observed increases in dopamine levels. To test this hypothesis, future
studies should determine changes in both extracellular dopamine and serotonin levels in this
brain region following administration of a range of doses of these two drugs.
The current studies are the first to report in vivo neurochemical effects of PAL-353, PAL-313,
and PAL-287 in nonhuman primates. Earlier studies examined the effect of PAL-287 on
altering basal dopamine and serotonin levels in the prefrontal cortex of rodents. Administration
of PAL-287 increased extracellular dopamine levels in the prefrontal cortex to the same extent
as administration of amphetamine did (about 700% baseline) (Rothman et al., 2005), which
contrasts with our current results in the nucleus accumbens of squirrel monkeys. In rodents,
serotonin levels were increased following PAL-287 administration (about 900% baseline), but
not following amphetamine administration (Rothman et al., 2005). Moreover, 3,4-
methylenedioxymethamphetamine (MDMA)-induced locomotor activity was positively
correlated with dopamine levels in the striatum, nucleus accumbens, and prefrontal cortex, as
well as with serotonin levels in the striatum and prefrontal cortex of rodents. In the same study,
stereotypy was positively correlated with dopamine levels in the striatum and nucleus
accumbens and with serotonin levels in all three brain regions (Baumann et al., 2008). While
the rodent data suggest that behavioral-stimulant effects of monoamine releasers are positively
associated with increases in both dopamine and serotonin, nonhuman primate data suggest that
increases in these behavioral effects are positively associated with increases in dopamine and
are negatively associated with increases in serotonin.
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In addition, these studies are the first reported microdialysis studies conducted in the nucleus
accumbens of squirrel monkeys. Other groups have conducted studies in this brain region in
rodents (Hooks et al., 1992; Steketee et al., 1992) and rhesus macaques (Bradberry et al.,
2000). To date, most microdialysis studies in squirrel monkeys have focused on neurochemical
changes in the caudate (Czoty et al., 2002; Czoty et al., 2000; Czoty et al., 2004; Ginsburg et
al., 2005; Kimmel et al., 2005; Kimmel et al., 2007), although the putamen (Davis et al.,
1997) and hippocampus (Ludvig et al., 2000) in this species have also been targeted. The
present study confirms that the nucleus accumbens is an accessible and viable region for
assessing experimentally-induced changes in neurotransmitter levels in this species.
Significant efforts have been directed toward the development of substitute agonists to treat
cocaine abuse. For example, continuous treatment with amphetamine, which selectively
releases dopamine and norepinephrine, dose-dependently decreased cocaine self-
administration in rhesus monkeys under both progressive ratio and choice schedules (Negus,
2003; Negus and Mello, 2003a, b). In humans, studies show that treatment with amphetamine
reduced cocaine use with little or no toxicity (Grabowski et al., 2001; Grabowski et al.,
2004). Although amphetamine may appear to be an effective treatment for cocaine abuse and
dependence, it has a high abuse liability, which may not be ideal for an effective medication.
Accordingly, drugs that are structurally similar to amphetamine are being considered as
potential medications and have been administered to rhesus monkeys that were initially trained
to self-administer cocaine in order to assess the reinforcing effects of these amphetamine
analogs. The potencies of four amphetamine analogs as a reinforcer in both fixed-ratio and
progressive-ratio schedules did not correlate with the in vitro potencies of these analogs to
release dopamine or serotonin. However, there was a very strong correlation between the ratio
of the in vitro potencies for releasing dopamine versus serotonin and their reinforcing potency
in both schedules of self-administration (Wee et al., 2005). These results indicate that
increasing the selectivity for releasing dopamine versus serotonin increases the reinforcing
effects of these drugs. As the drug becomes relatively more potent in releasing serotonin, the
reinforcing effect decreases. These data support earlier studies that show increasing
serotonergic tone decreases cocaine self-administration in rodents (Peltier and Schenk, 1993;
Richardson and Roberts, 1991) and nonhuman primates (Czoty et al., 2002; Kleven and
Woolverton, 1993). Neurochemical studies also show that increasing serotonergic tone
attenuates cocaine-induced increases in dopamine in the caudate of squirrel monkeys (Czoty
et al., 2002).
Studies with monoamine transporter inhibitors have shown that the behavioral profile of
cocaine is influenced by actions on multiple neurotransmitters. Inhibition of SERT decreased
cocaine self-administration in both rodents and nonhuman primates (Carroll et al., 1990; Czoty
et al., 2002; Kleven and Woolverton, 1993). These SERT inhibitors also attenuated the
behavioral-stimulant effects of cocaine in squirrel monkeys (Howell and Byrd, 1995;
Spealman, 1993). Furthermore, inhibition of both DAT and SERT produced more robust
reductions in cocaine self-administration in rhesus monkeys than did inhibition of DAT alone
(Howell et al., 2007), providing additional support for targeting both of these neurotransmitters.
Human patients receiving the combination of the dopamine releaser phentermine and the
serotonin releaser fenfluramine as medications showed that the concurrent dopamine and
serotonin release can ameliorate the symptoms of cocaine withdrawal and reduce illicit cocaine
use (Kampman et al., 2000; Rothman et al., 1994). These preclinical and clinical findings
support the rationale for the development of compounds that release both dopamine and
serotonin as potential treatment medications for stimulant addiction.
The data presented here suggest that PAL-313 should be considered as a potential
pharmacotherapeutic treatment for cocaine addiction, as it significantly elevates dopamine
levels but does not have appreciable behavioral-stimulant effects in nonhuman primates.
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Furthermore, this compound maintained very low self-administration behavior in rhesus
monkeys trained under a fixed-ratio schedule or those trained in a progressive-ratio schedule
(Wee et al., 2005), suggesting that this drug is not reinforcing. Thus, this drug has several
characteristics that render it favorable as a medication for treating psychostimulant addiction
(Vocci et al., 2005).
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Chemical structures of amphetamine and the four structurally related drugs used in these
studies.
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Increases in extracelluar dopamine following i.m. administration of each of the four drugs.
Data (mean ± SEM) are presented as a percent of baseline dopamine levels prior to drug
injection in each study. *p < 0.05, as compared to baseline using Dunnett’s post-hoc test.
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Dose-effect curve of increases in rates of responding following i.m. administration of each
drugs. Data (mean ± SEM) are presented as a percent of the rate of lever pressing following
i.m. administration of vehicle. These rates were averaged across the entire 90-min session,
resulting in one data point for each dose administered. The dotted line represents baseline
responding rates following i.m. administration of saline. *p < 0.05, as compared to vehicle
using Dunnett’s post-hoc tests.
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Time course of increases in rates of responding following i.m. administration of 0.3 mg/kg or
1.0 mg/kg amphetamine (panel A) or 0.3 mg/kg or 1.0 mg/kg PAL-353 (panel B). Data (mean
± SEM) are presented as a percent of the rate of lever pressing following i.m. administration
of saline. The dotted line represents baseline responding rates following i.m. administration of
saline. *** p < 0.001, ** p < 0.01, * p < 0.05, as compared to vehicle at that time point using
Bonferroni post-hoc tests.
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TABLE 1
In vitro potency as releasers of monoamine neurotransmitters in rodent brain tissue.
EC50 (nM)
Drug [3H]DA [3H]5-HT DA/5-HT
d-Amphetaminea 8.0 1756 0.004
PAL-353a 24.2 1937 0.01
PAL-313a 44.1 53.4 0.83
PAL-287b 12.6 3.4 3.7
Fenfluramineb >10,000 79.3 126.1
a
Modified from Wee et al., 2005 and
b
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